DC
SEEL

Davenport & Co’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Davenport & Co’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3
Closed -$1.84K – 1121
2023
Q3 		$1.84K Buy
+3
New +$12.9K ﹤0.01% 1048

Other funds holding SEEL

Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $9.37B AUM 23.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Davenport & Co's SEEL Position: Q4 2023 in Review

Davenport & Co sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2023, closing a stake of 38 shares — an estimated $26.8K sold.

Davenport & Co first reported a position in SEEL in Q1 2020 and held it in 14 quarters. The position peaked at $1.21M in Q1 2021. 32 funds tracked by Wall St. Rank hold SEEL as of Q4 2023.

  • Davenport & Co reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Davenport & Co sold 38 Seelos Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $26.8K.
  • Davenport & Co first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2020 and held it in 14 quarters.
  • Davenport & Co's Seelos Therapeutics, Inc. Common Stock position peaked at $1.21M in Q1 2021.
  • 32 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Davenport & Co's 13F filing for Q4 2023, filed 23 Jan 2024.